Alligator receives approximately SEK 13.8 million through the exercise of warrants of series TO 6
The exercise period for warrants series TO 6 in Alligator Bioscience AB (publ) (“Alligator” or the “Company”) ended on 31 August 2023. A tot ...
Last day of trading in paid subscribed units (Sw. BTU) in Alligator
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator announces final outcome of rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator announces preliminary outcome of rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator intends to carry out a 91 percent secured rights issue of units of approximately SEK 199 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Issue and repurchase of series C shares for performance-based share saving program
Pursuant to the authorization granted by the annual general meeting on 1 June 2021, the board of directors of Alligator Bioscience AB (”Alli ...
Alligator carries out a fully guaranteed rights issue of approximately SEK 86m
The Board of Directors of Alligator Bioscience AB (publ) ("Alligator" or the "Company") has today, based on the authorizatio ...